

POSTER PRESENTATION

Open Access

High-dose IL-2 in metastatic melanoma: better survival in patients who also received patient-specific autologous tumor cell vaccine

Robert O Dillman^{1,2,3*}, Carol DePriest³, Stephanie E McClure^{1,2}

From Society for Immunotherapy of Cancer 28th Annual Meeting
National Harbor, MD, USA. 8-10 November 2013

Treatment with high-dose Interleukin-2 (IL-2) has been associated with long-term survival in small proportion of metastatic melanoma patients. We recently reported a median survival of 15.6 months, and a 20% 5-year survival rate for 150 such patients who were hospitalized for high-dose i.v. IL-2 between May 1987 and April 2010. [1] A recent report showed a survival advantage for the addition of gp100 vaccine plus high-dose IL-2 compared to treatment with IL-2 alone [2]. We were aware that several of our IL-2 patients had also received patient-specific tumor cell vaccines derived from autologous tumor cell lines. We wished to determine whether this may have contributed to their high 5-year survival rate. Comparison of existing data bases revealed that 27 of the 150 IL-2 patients had also received a patient-specific vaccine; 123 had not. The table below (Table 1) summarizes survival data, which was calculated from the date IL-2 was initiated. Survival was much better in patients who received a patient-specific vaccine in addition to IL-2 ($p < 0.001$). That group was also younger, but age was not a predictor of survival in as much as median and 5-year survival rates were not dissimilar: 14.1 months and 23% for patients age < 50 years at the time of IL-2, compared to 15.9 months and 17% for patients $>$ age of 50 (NSD). Of the 27 vaccine patients, 7 started vaccine therapy an average of 8.7 mos. before receiving IL-2 (range 2.4 to 40 mos.) and 20 received vaccine a median of 14.2 months after starting IL-2 (range 1 to 42 mos.); 12 received injections of irradiated autologous tumor cells and 15 received injections of dendritic cells loaded with antigens from irradiated autologous tumor cells, and suspended in 500

Table 1

Therapy	IL-2	IL-2 + Vaccine
Portion female	58%	59%
Median age at diagnosis	50 yrs	40 yrs
Median age at IL-2	54 yrs	44 yrs
Median age at vaccine	N/A	47
Median survival from IL-2	12.8 mos	40.3 mos
5-year survival from IL-2	14%	44%

microgram GM-CSF. Survival was longer in patients who received IL-2 first (5-yr survival 55% vs 14%), and in patients who received the dendritic cell vaccine (5-yr survival 53% vs 33%). This analysis suggests that receipt of high-dose IL-2 followed by a patient specific vaccine results in better survival than IL-2 alone, but the limitations of such a retrospective analysis, and the risk of confounding unintended bias, are significant.

Authors' details

¹Hoag Institute for Research and Education, Hoag Hospital, Newport Beach, CA, USA. ²Hoag Family Cancer Institute, Hoag Hospital, Newport Beach, CA, USA. ³Cancer Biotherapy Research Group, Newport Beach, CA, USA.

Published: 7 November 2013

References

1. Dillman, *et al.*: *Cancer Radiopharm Biother* 2011.
2. Schwartzentruber, *et al.*: *N Engl J Med* 2010.

doi:10.1186/2051-1426-1-S1-P208

Cite this article as: Dillman *et al.*: High-dose IL-2 in metastatic melanoma: better survival in patients who also received patient-specific autologous tumor cell vaccine. *Journal for ImmunoTherapy of Cancer* 2013 **1**(Suppl 1):P208.

¹Hoag Institute for Research and Education, Hoag Hospital, Newport Beach, CA, USA

Full list of author information is available at the end of the article